Company profile for ITF Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ITF Therapeutics is the U.S.-based rare disease division of Italfarmaco S.p.A., a global pharmaceutical company with a legacy of innovation since 1938. Operating in over 90 countries, Italfarmaco has developed numerous therapeutic products addressing unmet medical needs. Launched in January 2024, ITF Therapeutics focuses on developing and commercializing treatments for rare diseases. Committed to collaboration, we partner with...
ITF Therapeutics is the U.S.-based rare disease division of Italfarmaco S.p.A., a global pharmaceutical company with a legacy of innovation since 1938. Operating in over 90 countries, Italfarmaco has developed numerous therapeutic products addressing unmet medical needs. Launched in January 2024, ITF Therapeutics focuses on developing and commercializing treatments for rare diseases. Committed to collaboration, we partner with patient advocacy and treatment communities to ensure our programs align with their needs, advancing impactful solutions for rare disease patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
300 Baker Avenue, Suite 280 Concord, MA 01742
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/new-data-presented-on-givinostat-for-treatment-of-duchenne-muscular-dystrophy-at-2025-neuromuscular-study-group-annual-scientific-meeting-302567931.html

PR NEWSWIRE
26 Sep 2025

https://www.prnewswire.com/news-releases/itf-therapeutics-announces-publication-of-positive-long-term-data-reinforcing-givinostat-efficacy-and-safety-as-a-treatment-for-duchenne-muscular-dystrophy-302537372.html

PR NEWSWIRE
25 Aug 2025

https://www.prnewswire.com/news-releases/itf-therapeutics-llc-announces-opening-of-new-us-headquarters-in-concord-massachusetts-302393162.html

PR NEWSWIRE
05 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty